Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab + Ofatumumab in Previously Untreated Symptomatic CLL (Phase 2)
2010-024389-23Phase 2Completed
- Sponsor
- Department of Hematology
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab and ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Department of Hematology. Primary endpoints: Overall response rate by iwCLL 2008 and Minimal residual disease (MRD) assessment. Started Apr 2011; status: completed.
02
Drugs
alemtuzumabofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-024389-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024389-23.